• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CircGLIS3 inhibits thyroid cancer invasion and metastasis through miR-146b-3p/AIF1L axis
ConclusionOur study identified circGLIS3 as a novel tumor suppressor in thyroid cancer, indicating the potential of circGLIS3 as a promising diagnostic and prognostic marker for thyroid cancer.
Source: Cellular Oncology - August 23, 2023 Category: Cancer & Oncology Source Type: research

Targeting SHP2 reverses BRAF inhibitor tolerance in anaplastic thyroid carcinoma
CONCLUSION: The SHP2 inhibitor SHP099 can effectively reverse the drug resistance of dabrafenib through inhibiting the reactivated RAS signaling pathway in anaplastic thyroid cancer.The combination of dabrafenib with SHP2 inhibitor has shown significant tumor suppressive effects for dabrafenib-resistant cells and it may be a new therapeutic strategy with longer lasting therapeutic benefits.PMID:36786145 | DOI:10.2174/1871520623666230214093122
Source: Cancer Control - February 14, 2023 Category: Cancer & Oncology Authors: Tao Tang Jie Zhou Li-Xin Zhang Gang Yang Wei-Nan Li Jian-Jiao Zhu Yong-Fu Xiong Jing-Dong Li Source Type: research

Cancers, Vol. 15, Pages 1158: Unique Metabolic Contexts Sensitize Cancer Cells and Discriminate between Glycolytic Tumor Types
nning Cancer cells utilize variable metabolic programs in order to maintain homeostasis in response to environmental challenges. To interrogate cancer cell reliance on glycolytic programs under different nutrient availabilities, we analyzed a gene panel containing all glycolytic genes as well as pathways associated with glycolysis. Using this gene panel, we analyzed the impact of an siRNA library on cellular viability in cells containing only glucose or only pyruvate as the major bioenergetic nutrient source. From these panels, we aimed to identify genes that elicited conserved and glycolysis-dependent changes in cellu...
Source: Cancers - February 11, 2023 Category: Cancer & Oncology Authors: Jonathan A. Chacon-Barahona Jeffrey P. MacKeigan Nathan J. Lanning Tags: Article Source Type: research

Cancers, Vol. 14, Pages 5838: Suppression of Calcium Entry Modulates the Expression of TR & beta;1 and Runx2 in Thyroid Cancer Cells, Two Transcription Factors That Regulate Invasion, Proliferation and Thyroid-Specific Protein Levels
In conclusion, we show that TRβ1 is downregulated in thyroid cancer cells and that restoration of its expression can reverse the cancer cell phenotype towards a normal thyroid cell phenotype.
Source: Cancers - November 26, 2022 Category: Cancer & Oncology Authors: Muhammad Yasir Asghar Taru Knuutinen Emilia Holm Tommy Nordstr öm Van Dien Nguyen You Zhou Kid T örnquist Tags: Article Source Type: research

LGALS2 suppresses the progression of papillary thyroid carcinoma by regulating the PI3K/AKT pathway
CONCLUSIONS: These data indicate that LGALS2 suppresses PTC progression via PI3K/AKT pathway activation, suggesting that LGALS2 offers value as a treatment target for patients with this cancer type.PMID:36221286 | PMC:PMC9547712 | DOI:10.21037/gs-22-452
Source: Cancer Control - October 12, 2022 Category: Cancer & Oncology Authors: Debin Xu Liangyun Guo Shuyong Zhang Qian Hou Source Type: research

AHNAK2 promotes the progression of differentiated thyroid cancer through PI3K/AKT signaling pathway
CONCLUSION: Furthermore, the protein levels of phospho-PI3 Kinase p85 and phospho-AKT were down-regulated in the transfected TC cell. Our study results indicate that AHNAK2 may promote metastasis and proliferation of thyroid cancer through PI3K/AKT signaling pathway. Thus, AHNAK2 may be used as a candidate marker for TC diagnosis and treatment.PMID:36089788 | DOI:10.2174/1568009622666220908092506
Source: Current Cancer Drug Targets - September 12, 2022 Category: Cancer & Oncology Authors: Min Xu Jialiang Wen Qiding Xu Huihui Li Bangyi Lin Adheesh Bhandari Jinmiao Qu Source Type: research

Pages: 1  2  3  4  5